吡丙醚-菊酯和氯虫苯甲酰胺-菊酯长效杀虫蚊帐与纯菊酯长效杀虫蚊帐在分发后第三年疟疾控制效果比较:贝宁整群随机对照试验的二次分析
该研究为贝宁整群随机对照试验的二次分析,比较吡丙醚-菊酯和氯虫苯甲酰胺-菊酯长效杀虫蚊帐与纯菊酯蚊帐在分发后第三年的疟疾控制效果。第三年随访中,吡丙醚-菊酯组疟疾发病率与纯菊酯组无显著差异(HR 1.02,95%CI 0.71-1.44),氯虫苯甲酰胺-菊酯组亦无显著差异(HR 0.80,95%CI 0.56-1.17)。研究蚊帐使用率下降,可能影响结果。
要点
- 第三年吡丙醚-菊酯蚊帐组疟疾发病率与纯菊酯组无显著差异(HR 1.02,95%CI 0.71-1.44)。
- 第三年氯虫苯甲酰胺-菊酯蚊帐组疟疾发病率与纯菊酯组无显著差异(HR 0.80,95%CI 0.56-1.17)。
- 研究蚊帐使用率随时间下降,吡丙醚-菊酯组最低(36个月时39.4%)。
核心结论
- 第三年,吡丙醚-菊酯长效杀虫蚊帐组与标准纯菊酯蚊帐组相比,对疟疾病例的保护未显示出优势。
- 第三年,氯虫苯甲酰胺-菊酯长效杀虫蚊帐组居民不再比纯菊酯蚊帐组居民获得针对疟疾病例和感染的更多保护。
- 这一结果可能受研究蚊帐使用率低于既往年份及蚊帐中配对杀虫剂浓度下降的影响。
研究设计与样本
- 整群随机对照试验的二次分析,于2019年5月23日至2023年4月30日在贝宁南部开展。
- 采用限制性随机化将60个整群(村庄或村庄组,每群至少100户)按1:1:1分配至三组:吡丙醚-菊酯长效杀虫蚊帐组、氯虫苯甲酰胺-菊酯长效杀虫蚊帐组和纯菊酯长效杀虫蚊帐组(参照组)。
- 研究工作人员和社区对分组设盲。
- 主要结局为蚊帐分发后第三年,在入组时6月龄至9岁儿童队列中,意向性治疗人群的疟疾发病率。
- 试验注册于ClinicalTrials.gov,注册号NCT03931473。
主要发现
- 研究蚊帐使用率在3年内下降,吡丙醚-菊酯组始终最低:36个月时,吡丙醚-菊酯组889/2257例(39.4%),氯虫苯甲酰胺-菊酯组1278/2450例(52.2%),纯菊酯组1400/2430例(57.6%)。
- 第三年随访儿童队列(每组600例)于2022年4月9日至30日入组。
- 分发后第三年平均疟疾发病率:纯菊酯参照组为1.19例/儿童年(95%CI 1.09-1.29),吡丙醚-菊酯组为1.21例/儿童年(95%CI 1.12-1.31;HR 1.02,95%CI 0.71-1.44;p=0.92),氯虫苯甲酰胺-菊酯组为0.96例/儿童年(95%CI 0.88-1.05;HR 0.80,95%CI 0.56-1.17;p=0.25)。
- 参与者未报告与研究蚊帐相关的不良事件。
局限性
- 研究蚊帐使用率随时间下降,吡丙醚-菊酯组始终最低(36个月时39.4%)。
- 蚊帐中配对杀虫剂浓度下降。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Malaria continues to kill approximately 650 000 people each year. There is evidence that some second-generation insecticide-treated nets, which combine insecticide formulations with different modes of action, are protective against malaria while the nets are new; however, evidence for their impact over 3 years is scarce. In this study, we report the third-year results of a cluster-randomised controlled trial assessing the long-term effectiveness of dual-active ingredient long-lasting insecticidal nets (LLINs). METHODS: This is a secondary analysis of a cluster-randomised controlled trial, carried out between May 23, 2019, and April 30, 2023, in southern Benin. Restricted randomisation was used to assign 60 clusters (villages or groups of villages with a minimum of 100 households) to the three study groups (1:1:1) to evaluate the efficacy of pyriproxyfen-pyrethroid LLINs and chlorfenapyr-pyrethroid LLINs compared with pyrethroid-only LLINs (reference) against malaria transmission. The study staff and communities were masked to the group allocation. The primary outcome was malaria incidence measured over the third year after LLIN distribution, in a cohort of children aged 6 months to 9 years at the time of enrolment, in the intention-to-treat population. Here, we present the data of the third year post-LLIN distribution. The trial was registered with ClinicalTrials.gov, NCT03931473. FINDINGS: Study net use declined over the 3 years and was consistently lowest in the pyriproxyfen-pyrethroid LLIN group (at 36 months: 889 [39·4%] of 2257 participants vs 1278 [52·2%] of 2450 participants for the chlorfenapyr-pyrethroid LLIN group and 1400 [57·6%] of 2430 participants for the pyrethroid-only LLIN group). The cohort of children for the third year of follow-up (600 per group) were enrolled between April 9 and 30, 2022. Mean malaria incidence during the third year after distribution was 1·19 cases per child-year (95% CI 1·09-1·29) in the pyrethroid-only LLIN reference group, 1·21 cases per child-year (1·12-1·31) in the pyriproxyfen-pyrethroid LLIN group (hazard ratio [HR] 1·02, 95% CI 0·71-1·44; p=0·92), and 0·96 cases per child-year (0·88-1·05) in the chlorfenapyr-pyrethroid LLIN group (HR 0·80, 0·56-1·17; p=0·25). No adverse events related to study nets were reported by participants. INTERPRETATION: During the third year, as was also observed during the first 2 years, the pyriproxyfen-pyrethroid LLIN group did not have superior protection against malaria cases compared with the standard LLIN group. In the third year, people living in the chlorfenapyr-pyrethroid LLIN group no longer benefited from greater protection against malaria cases and infections than those living in the pyrethroid-only LLIN group. This was probably influenced by lower study net use than previous years and the declining concentration of partner insecticides in the nets. FUNDING: UNITAID, The Global Fund. TRANSLATION: For the French translation of the abstract see Supplementary Materials section.
引用
- Accrombessi M, Cook J, Dangbenon E, et al. Effectiveness of pyriproxyfen-pyrethroid and chlorfenapyr-pyrethroid long-lasting insecticidal nets (LLINs) compared with pyrethroid-only LLINs for malaria control in the third year post-distribution: a secondary analysis of a cluster-randomised controlled trial in Benin. Lancet Infect Dis. 2024. PMID: 38401551. doi:10.1016/S1473-3099(24)00002-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。